Rheum Practices Served
Clean Claim Rate
Revenue Recovered
Drug Claims
Rheumatology billing hinges on two revenue-critical areas: high-cost biologic drug infusions and the chronic disease management visits that surround them. Each biologic drug has its own prior authorization protocol, J-code, and wastage reporting requirement. The infusion administration coding must follow the correct hierarchy. And the E/M visits that monitor treatment response require documentation that supports ongoing medical necessity.
We handle rheumatology billing with deep knowledge of biologic drug billing, infusion administration hierarchies, and the chronic disease coding patterns that keep autoimmune patients on effective treatment while maintaining your revenue cycle.
Every Rheumatology billing team deals with payer delays, coding nuance, and collection leakage. We tighten those weak points before they turn into write-offs.
Every biologic drug (Remicade, Orencia, Rituxan, Actemra) requires prior authorization with documentation of diagnosis, disease severity, and failed conventional therapies. Step therapy requirements vary by payer and change frequently.
Biologic infusions follow the chemotherapy infusion hierarchy (96413-96417) or non-chemo infusion codes (96365-96368) depending on the drug. Selecting the wrong code set reduces reimbursement by 30% to 50%.
Single-use vials often contain more drug than the patient's dose requires. CMS requires JW modifier reporting for discarded amounts. Failing to report wastage correctly can trigger audits and recoupments.
Joint and soft tissue injections (20610, 20600-20604) performed alongside the office visit are frequently bundled by payers. Proper documentation and modifier usage ensure these procedures are reimbursed separately.
Support spans the full revenue cycle, from front-end verification to denial recovery and reporting.
Biologic drug infusion billing (Remicade, Orencia, Rituxan, Actemra)
Prior authorization management for biologic step therapy
Infusion administration hierarchy coding (chemo vs non-chemo)
Drug acquisition cost tracking and wastage (JW modifier) reporting
Joint and soft tissue injection coding (20600-20611)
Chronic disease management coding for autoimmune conditions
We support independent practices, multisite groups, and growing provider organizations with flexible workflows.
Independent physician groups
Multi-location practices
Private equity backed platforms
Hospital-owned outpatient groups
Rheumatology billing hinges on two revenue-critical areas: high-cost biologic drug infusions and the chronic disease management visits that surround them. Each biologic drug has its own prior authorization protocol, J-code, and wastage reporting requirement. The infusion administration coding must follow the correct hierarchy. And the E/M visits that monitor treatment response require documentation that supports ongoing medical necessity.
We handle rheumatology billing with deep knowledge of biologic drug billing, infusion administration hierarchies, and the chronic disease coding patterns that keep autoimmune patients on effective treatment while maintaining your revenue cycle.
Answers to the questions practice owners and managers ask most often before switching billing partners.
We manage the full prior auth cycle: compiling clinical documentation (disease activity scores, failed therapies, lab results), submitting to the payer or specialty pharmacy, tracking approval status, and managing renewals. When step therapy is required, we document each step to build the case for biologic approval.
Some biologic drugs (Rituxan, Orencia IV) are billed using chemotherapy infusion codes (96413-96417) because of their drug classification, while others (Remicade, Actemra IV) use therapeutic infusion codes (96365-96368). The code set affects reimbursement significantly, and we apply the correct codes based on CMS drug classification guidelines.
When a single-use vial contains more drug than the prescribed dose, we report the discarded amount using the JW modifier alongside the drug J-code. This documentation supports the full vial billing and complies with CMS wastage reporting requirements. We track wastage per drug per patient for audit readiness.
Yes. Joint injections (20610 for large joints, 20605 for intermediate, 20600 for small) and trigger point injections (20552-20553) are billed with the appropriate injection code plus the drug administered. When performed on the same day as an E/M visit, we use modifier 25 on the E/M code with supporting documentation.
The most frequently used diagnosis codes include M05-M06 (rheumatoid arthritis), M32 (systemic lupus), M34 (systemic sclerosis), M35.9 (undifferentiated connective tissue disease), and M45 (ankylosing spondylitis). Accurate diagnosis coding is essential for prior authorization approvals and payer reimbursement.
For buy-and-bill drugs (infused in-office), we bill the drug J-code and infusion administration codes directly to the payer. For specialty pharmacy drugs (self-injected at home), we coordinate the prescription benefit billing and assist with copay assistance program enrollment. We help practices evaluate which model generates better margins for each drug.
The difference is operational discipline. We focus on clean submissions, fast follow-up, and transparency.
Get a revenue review and a clear action plan tailored to your practice, payers, and claim mix.